Grace Capital cut its position in Pfizer Inc. (NYSE:PFE) by 26.9% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,152 shares of the biopharmaceutical company’s stock after selling 3,000 shares during the period. Grace Capital’s holdings in Pfizer were worth $319,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. OLD Mission Capital LLC bought a new stake in shares of Pfizer during the third quarter worth $291,000. Lehman & Derafelo Financial Resources LLC grew its position in Pfizer by 3.6% in the first quarter. Lehman & Derafelo Financial Resources LLC now owns 212,511 shares of the biopharmaceutical company’s stock valued at $7,699,000 after purchasing an additional 7,354 shares in the last quarter. Ironwood Wealth Management LLC. grew its position in Pfizer by 1.6% in the first quarter. Ironwood Wealth Management LLC. now owns 35,385 shares of the biopharmaceutical company’s stock valued at $1,282,000 after purchasing an additional 550 shares in the last quarter. Petix & Botte Co bought a new position in Pfizer in the first quarter valued at $187,000. Finally, Advisors Preferred LLC grew its position in Pfizer by 66.0% in the first quarter. Advisors Preferred LLC now owns 12,686 shares of the biopharmaceutical company’s stock valued at $461,000 after purchasing an additional 5,045 shares in the last quarter. Institutional investors own 64.93% of the company’s stock.
PFE has been the subject of a number of analyst reports. The Goldman Sachs Group set a $48.00 target price on shares of Pfizer in a research report on Thursday, July 29th. JPMorgan Chase & Co. raised their target price on shares of Pfizer from $40.00 to $42.00 and gave the company a “neutral” rating in a research report on Monday, September 13th. SVB Leerink lifted their price objective on shares of Pfizer from $49.00 to $50.00 and gave the company a “market perform” rating in a research report on Monday. Mizuho lifted their price objective on shares of Pfizer from $42.00 to $43.00 and gave the company a “neutral” rating in a research report on Friday, July 30th. Finally, Berenberg Bank reissued a “neutral” rating and issued a $43.00 price objective on shares of Pfizer in a research report on Tuesday, June 15th. Eleven investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $42.85.
NYSE PFE opened at $43.58 on Monday. The firm has a 50-day moving average of $45.04 and a 200-day moving average of $40.57. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.12 and a current ratio of 1.37. The stock has a market cap of $244.34 billion, a PE ratio of 18.55, a P/E/G ratio of 1.58 and a beta of 0.74. Pfizer Inc. has a 52-week low of $33.36 and a 52-week high of $51.86.
Pfizer (NYSE:PFE) last posted its earnings results on Wednesday, July 28th. The biopharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.97 by $0.10. Pfizer had a net margin of 23.06% and a return on equity of 26.49%. The company had revenue of $18.98 billion during the quarter, compared to analysts’ expectations of $17.54 billion. During the same quarter last year, the company posted $0.78 EPS. As a group, analysts predict that Pfizer Inc. will post 4.12 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 7th. Shareholders of record on Friday, July 30th were paid a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 3.58%. The ex-dividend date of this dividend was Thursday, July 29th. Pfizer’s dividend payout ratio (DPR) is 70.27%.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
Further Reading: Understanding Relative Strength Index
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.